Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study.

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2022
This article has no abstract
Epistemonikos ID: 562684341bf8fda927696d9935864cd5e0b3eb64
First added on: Feb 14, 2025